Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

SCLC, Limited Stage 1Neuroblastoma 1Neoplasms 1Lung Neoplasms 1Heart Failure 1Carcinoma, Non-Small-Cell Lung 1Arrhythmias, Cardiac 1Anemia 1

Interventions

Darbepoetin alfa 19Epoetin Alfa 17ACE-011 4Cyclosporine 3Busulfan 3luspatercept 2fludarabine phosphate 2fludarabine 2ferric carboxymaltose 2epoetin beta 2continuous erythropoietin receptor activator 2Methotrexate 2Iron-Dextran Complex 2Filgrastim 2Cyclophosphamide 2vactosertib 1thymoglobulin 1ruxolitinib 1roxadustat 1peginesatide 1pegfilgrastim 1niraparib 1leridistim 1iron isomaltoside 1000 1hematide 1ferric gluconate 1eltrombopag 1angiotensin I (1-7) 1Therapeutics 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia × Population Groups × Clear all
NCT06737081 2024-12-17

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 2 Recruiting
60 enrolled
Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡